Meet our SPARK Fellows
Introducing Cohort 8
Zhirui Wang, PhD
CCR4 Immunotoxin for Cancer Immunotherapy via Treg Depletion
Email Address:ZHIRUI.WANG@CUANSCHUTZ.EDU
CCR4 Immunotoxin for Cancer Immunotherapy via Treg Depletion
This project aims to overcome the immunosuppressive tumor microenvironment (TME) by targeting tumor-infiltrating effector Tregs, which hinder antitumor immune responses. The researchers have developed a novel CCR4 immunotoxin (CCR4-IT) to specifically deplete tumor-infiltrating Tregs for broad-spectrum cancer treatment. They plan to evaluate the efficacy of this immunotoxin using humanized mouse tumor models. The data generated from these studies will be utilized to secure further funding or attract commercial investment, with the ultimate goal of advancing this technology into clinical trials for Treg-targeted immunotherapy, potentially revolutionizing cancer treatment.
Learn more about Dr. WangCohort 7
Cohort 6
Zhirui Wang, PhD
CCR4 Immunotoxin for Cancer Immunotherapy via Treg Depletion
Email Address:ZHIRUI.WANG@CUANSCHUTZ.EDU
CCR4 Immunotoxin for Cancer Immunotherapy via Treg Depletion
This project aims to overcome the immunosuppressive tumor microenvironment (TME) by targeting tumor-infiltrating effector Tregs, which hinder antitumor immune responses. The researchers have developed a novel CCR4 immunotoxin (CCR4-IT) to specifically deplete tumor-infiltrating Tregs for broad-spectrum cancer treatment. They plan to evaluate the efficacy of this immunotoxin using humanized mouse tumor models. The data generated from these studies will be utilized to secure further funding or attract commercial investment, with the ultimate goal of advancing this technology into clinical trials for Treg-targeted immunotherapy, potentially revolutionizing cancer treatment.
Learn more about Dr. WangCohort 5
Zhirui Wang, PhD
CCR4 Immunotoxin for Cancer Immunotherapy via Treg Depletion
Email Address:ZHIRUI.WANG@CUANSCHUTZ.EDU
CCR4 Immunotoxin for Cancer Immunotherapy via Treg Depletion
This project aims to overcome the immunosuppressive tumor microenvironment (TME) by targeting tumor-infiltrating effector Tregs, which hinder antitumor immune responses. The researchers have developed a novel CCR4 immunotoxin (CCR4-IT) to specifically deplete tumor-infiltrating Tregs for broad-spectrum cancer treatment. They plan to evaluate the efficacy of this immunotoxin using humanized mouse tumor models. The data generated from these studies will be utilized to secure further funding or attract commercial investment, with the ultimate goal of advancing this technology into clinical trials for Treg-targeted immunotherapy, potentially revolutionizing cancer treatment.
Learn more about Dr. Wang